AI CAPITAL INTELLIGENCE
WhiteLab Genomics · Series B · EUR 23,200,000 · 2026-10-06
Financing facts, at a glance
WhiteLab Genomics: financing disclosed on 2026-10-06, Series B, EUR 23,200,000. Named investors: AVP, Yaday Health, Blast Club, Omnes Capital, Debiopharm Innovation Fund. This is the amount disclosed for the financing, not a company valuation or an individual investor commitment.
WhiteLab Genomics is recorded in the Industry AI / Drug discovery & life sciences segment. The disclosed financing is Series B, with an amount of EUR 23,200,000. Named investors include AVP, Yaday Health, Blast Club, Omnes Capital, Debiopharm Innovation Fund.
- Disclosed company name
- WhiteLab Genomics
- Disclosure date
- 2026-10-06
- Round
- Series B
- Financing amount
- EUR 23,200,000
- Market coverage
- Outside China
- Sector
- Industry AI / Drug discovery & life sciences
- Product form
- Enterprise software
Disclosed investors
AVP, Yaday Health, Blast Club, Omnes Capital, Debiopharm Innovation Fund
Original sources
Record reviewed as of . Reported ranges and lower bounds are retained. Financing proceeds are not company valuation.